Daily Positive Signals: a medical resupply run, a balloon-weather deal, and a lung drug’s Phase 3 win
On this page
Listen to this brief · about 6 min, story text only
A SpaceX Dragon is headed to the International Space Station today carrying brain organoids and hardware to manufacture artificial retinas. The U.S. Air Force signed a contract worth up to $49 million for atmospheric data gathered by autonomous weather balloons. A new drug for idiopathic pulmonary fibrosis met its Phase 3 primary endpoint. And Meta released its first true frontier AI models. This edition’s thread: the real world, measured and improved.
In this edition · 4 signals
- A Dragon full of health research heads to the space station — Space
- The Air Force bets up to $49 million on smart weather balloons — AI infrastructure
- A new lung-scarring drug hits its Phase 3 endpoint — Pulmonary medicine
- Meta enters the frontier-model race for real — AI industry
Signal 1 of 4 · Space
A Dragon full of health research heads to the space station
A SpaceX Falcon 9 is scheduled to lift off from Cape Canaveral at 6:33 a.m. EDT today, October 13, carrying the 35th commercial resupply mission to the International Space Station (NASA, 2026a). Aboard are four investigations into human and plant health: lab-grown models of the human brain that will spend five weeks in orbit to reveal how short spaceflight affects the brain at the cellular level, a study of whether crop diseases progress faster in microgravity, the first test of a compact microplate reader that can analyze biomarkers aboard the station instead of waiting for samples to return to Earth, and the fourth stay of a study tracking how antibiotic-resistant bacteria evolve in microgravity (NASA, 2026b). The manifest also includes hardware to manufacture artificial retinas in microgravity, 3D heart-tissue models for large-scale drug testing, and the final pair of International Space Station Roll-Out Solar Arrays, completing the station’s power upgrade (NASA, 2026a; Fox 35 Orlando, 2026).
Why it matters. Brain organoids in orbit could surface treatment targets for Alzheimer’s, Parkinson’s, and multiple sclerosis. Onboard diagnostics would let future crews detect infections quickly when Earth is too far away to ask for help.
Evidence status: Official NASA releases plus independent local and trade press. Launch and docking times are planned; Dragon is expected to dock October 15 and return to Earth in mid-November.
Signal 2 of 4 · AI infrastructure
The Air Force bets up to $49 million on smart weather balloons
The U.S. Air Force awarded WindBorne Systems a sole-source contract worth up to $48.7 million for global atmospheric data, running through September 30, 2033, according to the Department of Defense contract record (Defence Blog, 2026). The Redwood City startup flies roughly 700 engineless balloons that steer by altitude — venting gas to descend, dropping ballast to climb — and feeds their sensor readings directly into its deep-learning WeatherMesh forecasting models (TechCrunch, 2026). The contract is pay-as-needed: the Air Force can order data for specific regions at specific times, and has so far ordered $1.7 million worth. It was awarded without competition after the government determined WindBorne was the only company able to provide this global data capability (TechCrunch, 2026). In August the company became the first to fly an unpowered system into the eye of a typhoon, using a deep-learning model for operational flight decisions (TechCrunch, 2026).
Why it matters. Forecast skill is gated by data as much as by models. A data pipeline nobody else can replicate, now validated by military procurement, is a strong moat — and better forecasts reach civilian weather services too.
Evidence status: U.S. Department of Defense contract record plus independent tech-press reporting. Only $1.7 million has been ordered so far; the rest of the ceiling is spent only if the Air Force places more orders.
Signal 3 of 4 · Pulmonary medicine
A new lung-scarring drug hits its Phase 3 endpoint
Bristol Myers Squibb reported that admilparant, its investigational oral lysophosphatidic acid receptor 1 (LPA1) antagonist, met the primary endpoint of the pivotal Phase 3 ALOFT-IPF trial (Bristol Myers Squibb, 2026). The 60 mg twice-daily dose produced a statistically significant improvement in absolute change in forced vital capacity — the key measure of breathing capacity — from baseline to week 52 versus placebo, in a 1:1:1 randomized trial of about 1,255 adults aged 40 and older (Bristol Myers Squibb, 2026; HCPLive, 2026). The drug was well tolerated, with discontinuations due to adverse events low and similar to placebo (Bristol Myers Squibb, 2026).
Why it matters. Idiopathic pulmonary fibrosis progressively scars the lungs and has only treatments that slow decline. A first-in-class oral drug with a new mechanism could become a genuine treatment option — if the full data hold up.
Evidence status: Company topline release plus independent clinical and trade press (HCPLive, BioPharma Dive). Caution: the higher 120 mg dose slowed decline but did not reach statistical significance, and the company disclosed no effect sizes, confidence intervals, or p-values, so the dose response is unresolved. The drug is investigational and not approved; detailed results are expected at a future medical meeting.
Signal 4 of 4 · AI industry
Meta enters the frontier-model race for real
Meta’s Superintelligence Labs released two models on Monday, October 12: Muse Wonder, available through the Meta Model API and Muse Code, and Muse Wonder Full, reserved for Muse Code subscribers (Meta, 2026). Both are built for agent work — long tasks where the model uses tools across several apps — with two signature features: Active Memory, which keeps key facts across a conversation, and Active Focus, which sticks with hard problems and asks follow-up questions (Meta, 2026). Independent benchmarker Artificial Analysis scored Wonder Full at 56 on its Intelligence Index, tying Claude Sonnet 5.5 and beating GPT-6 Astra at 53, with only Anthropic’s flagship Opus 5.5 higher at 58 (VentureBeat, 2026). Notably, both models are closed — a break from Meta’s earlier open-weights Llama era (VentureBeat, 2026).
Why it matters. Enterprise AI buyers just gained a serious third option beyond OpenAI and Anthropic. The September 30 edition of this brief tracked near-flagship models getting cheaper; now the frontier itself has another competitor.
Evidence status: Company announcement plus independent press and an independent benchmarker. Benchmark claims rest partly on Meta’s own tests; Meta has not published parameter counts or training details, and Wonder Full has no public API yet. Factual-knowledge scores lag rivals, per Artificial Analysis (VentureBeat).
Editor’s note
This edition is about measurement under pressure. In orbit, tiny brain models stand in for the brains astronauts need to keep healthy. In the stratosphere, balloons chase the wind patterns that models need to forecast storms. In the clinic, a trial measures lung function to the milliliter. And in the data center, new models are scored to the point. Different domains, one discipline: define what you need to know, measure it honestly, and let the results decide.
That’s the edition — four signals, every claim verified against its sources. Browse past briefs · tomorrow’s lands at 07:15.
The Progress Brief, by email
Useful progress, without the hype
The daily Positive Signals brief and the weekly deep dive, by email. Evidence-checked, concise, no doom.
Free. One daily email, one weekly email. Unsubscribe anytime.
References
- BioPharma Dive. (2026, October 12). Bristol Myers dips on ‘confounding’ lung drug results. https://www.biopharmadive.com/news/bristol-myers-admilparant-lpa1-ipf-aloft-results-contineum/832715/
- Bristol Myers Squibb. (2026, October 12). Bristol Myers Squibb announces Phase 3 ALOFT-IPF trial evaluating admilparant in adults with idiopathic pulmonary fibrosis met primary endpoint. Business Wire. https://www.businesswire.com/news/home/20261011397472/en/Bristol-Myers-Squibb-Announces-Phase-3-ALOFT-IPF-Trial-Evaluating-Admilparant-in-Adults-with-Idiopathic-Pulmonary-Fibrosis-Met-Primary-Endpoint
- Defence Blog. (2026, October 2). U.S. Air Force buys weather data from smart balloons. https://defence-blog.com/u-s-air-force-buys-weather-data-from-smart-balloons/
- Fox 35 Orlando. (2026, October 13). SpaceX CRS-35 launch could bring sonic booms, ‘space jellyfish’ to Central Florida. https://fox35orlando.com/news/nasa-spacex-crs-35-launch
- HCPLive. (2026, October 12). ALOFT-IPF: Admilparant 60 mg meets primary FVC end point. https://www.hcplive.com/view/aloft-ipf-admilparant-60-mg-meets-primary-fvc-end-point
- Meta. (2026, October 12). Meta adds memory and focus to new frontier models for agents [Press release reported by PYMNTS]. https://www.pymnts.com/news/artificial-intelligence/2026/meta-adds-memory-focus-new-frontier-models-agents/
- NASA. (2026a, October 7). NASA sets coverage for SpaceX 35th station resupply launch, arrival. https://www.nasa.gov/news-release/nasa-sets-coverage-for-spacex-35th-station-resupply-launch-arrival/
- NASA. (2026b, October 12). NASA’s SpaceX CRS-35 mission to launch health research. NASA Science. https://science.nasa.gov/missions/station/nasas-spacex-crs-35-mission-to-launch-health-research/
- Particle News. (2026, October 12). SpaceX carries final iROSA arrays to ISS in CRS-35 launch. https://particle.news/story/spacex-carries-final-irosa-arrays-to-iss-in-crs35-launch
- TechCrunch. (2026, October 12). WindBorne wins a hefty US Air Force contract for its balloon data. https://techcrunch.com/2026/10/12/windborne-wins-a-hefty-us-air-force-contract-for-its-balloon-data
- VentureBeat. (2026, October 12). Meta’s new Muse Wonder and Muse Wonder Full models achieve frontier performance, but only the weaker one is available via API. VentureBeat
